Shares of Novartis AG (NYSE:NVS – Get Rating) have received an average rating of “Hold” from the twenty analysts that are presently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have covered the stock in the last year is $85.20.
Several analysts recently issued reports on the company. Morgan Stanley cut their target price on Novartis from CHF 97 to CHF 88 in a research note on Thursday, September 8th. Oddo Bhf cut Novartis from an “outperform” rating to a “neutral” rating and set a CHF 88 price objective on the stock. in a research report on Thursday, September 29th. Kepler Capital Markets raised Novartis from a “hold” rating to a “buy” rating and set a CHF 90 price objective on the stock in a research report on Wednesday, September 7th. StockNews.com started coverage on Novartis in a research report on Wednesday, October 12th. They set a “strong-buy” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft dropped their price target on Novartis from CHF 75 to CHF 70 and set a “sell” rating on the stock in a research report on Friday, October 7th.
Novartis Stock Down 1.3 %
NYSE NVS opened at $84.02 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.31 and a quick ratio of 1.07. The stock has a market capitalization of $185.90 billion, a PE ratio of 8.64, a PEG ratio of 2.40 and a beta of 0.55. Novartis has a 1 year low of $74.09 and a 1 year high of $94.26. The business’s 50-day moving average is $78.88 and its 200 day moving average is $83.22.
Institutional Investors Weigh In On Novartis
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.
- Get a free copy of the StockNews.com research report on Novartis (NVS)
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn’t Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don’t Want to Get Stuck On
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.